Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Imatinib Mesylate Pharmacokinetics Before and After Sleeve Gastrectomy in a Morbidly Obese Patient with Chronic Myeloid Leukemia
Pharmacotherapy, 08/27/09
Pavlovsky C et al. – The patient remained in complete molecular remission for 1 year after surgery. Monitoring plasma imatinib concentrations is recommended in morbidly obese patients with chronic myeloid leukemia or gastrointestinal stromal tumors who undergo gastric procedures.
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 11/17/09
Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/03/09
Adjuvant Chemotherapy in Localized Soft Tissue Sarcomas: Still Not Proven
The Oncologist, 10/28/09
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
U-500 Regular Insulin: Clinical Experience and Pharmacokinetics in Obese, Severely Insulin Resistant Type 2 Diabetic Patients
Diabetes Care, 11/16/09
The role of ceramide in major depressive disorder
European Archives of Psychiatry and Clinical Neuroscience, 11/12/09
Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas
Clinical Cancer Research, 11/20/09
Today in Stomach/GI...keeping you current
Receive free subspecialty "5-minute updates" via email
Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09
Methotrexate for maintenance of remission in Crohn's disease
Cochrane Reviews, 10/27/09
Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin
Journal of Viral Hepatitis, 11/09/09
Sponsor
Article Search
Sponsor


See Latest Articles


